Astellas signs exclusive deal with AviadoBio for FTD-GRN gene therapy, investing $20m and offering up to $2.18bn in potential fees and royalties.

Astellas Pharma has signed an exclusive option and license agreement with AviadoBio for AVB-101, a gene therapy targeting frontotemporal dementia with progranulin mutations (FTD-GRN), currently in Phase 1/2 trials. Astellas will invest $20 million and pay up to $30 million initially for licensing rights. If exercised, the deal could yield AviadoBio up to $2.18 billion in fees and royalties, enhancing Astellas' gene therapy portfolio for neurodegenerative diseases.

October 08, 2024
4 Articles